![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/14/2881212/0/en/Acumen-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/05/13/2880837/0/en/Acumen-Pharmaceuticals-to-Participate-in-the-H-C-Wainwright-2nd-Annual-BioConnect-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/05/08/2877741/0/en/Acumen-Pharmaceuticals-Announces-First-Patient-Dosed-in-ALTITUDE-AD-a-Phase-2-Clinical-Trial-of-Sabirnetug-ACU193-in-Early-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/05/08/2878369/0/en/Acumen-Pharmaceuticals-to-Participate-in-the-2024-Bank-of-America-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/07/2877168/0/en/Acumen-Pharmaceuticals-to-Report-First-Quarter-Results-on-May-14-2024.html
https://www.globenewswire.com/news-release/2024/04/16/2863530/0/en/Acumen-Pharmaceuticals-Presents-First-Comprehensive-Clinical-and-Biomarker-Data-for-Sabirnetug-ACU193-at-American-Academy-of-Neurology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/04/2857726/0/en/Acumen-Pharmaceuticals-Collaborates-with-Lonza-to-Advance-Sabirnetug-for-the-Treatment-of-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/03/26/2852230/0/en/Acumen-Pharmaceuticals-Reports-Financial-Results-for-the-Year-Ended-December-31-2023-and-Business-Highlights.html
https://www.globenewswire.com/news-release/2024/03/21/2850184/0/en/Acumen-Pharmaceuticals-to-Present-Deeper-Insights-Including-Fluid-Biomarker-Data-for-Sabirnetug-ACU193-During-Emerging-Science-Session-at-the-American-Academy-of-Neurology-Annual-M.html
https://www.globenewswire.com/news-release/2024/03/19/2848953/0/en/Acumen-Pharmaceuticals-to-Report-Fourth-Quarter-and-Year-End-2023-Financial-Results-on-March-26-2024.html